Actelion Ltd (ALIOF) 150.8840 $ALIOF Relapsing Remitting

New Post Public Reply Private Reply Replies (0) Message Board

Jul 11, 2015 at 1:40 PM

Actelion Ltd (ALIOF) 150.8840 $ALIOF

Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics Pipeline Review, H1 2015 - 27 Companies & 33 Drug profiles
M2 - Thu Jul 09, 9:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hdmmpc/relapsing) has announced the addition of the "Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Actelion Ltd - Allozyne, Inc. - Amarna Therapeutics B.V. - Antisense Therapeutics Limited - Biogen, Inc. - Cognosci, Inc. - F. Hoffmann-La Roche Ltd. - Forward Pharma A/S - Genmab A/S - GlaxoSmithKline plc - Iltoo Pharma - Mapi Pharma Ltd. - MedImmune, LLC - Merck KGaA - Mitsubishi Tanabe Pharma Corporation - Neurotec Pharma SL - Novartis AG - Nuron Biotech, Inc. - Octapharma AG - Opexa Therapeutics, Inc. - RedHill Biopharma Ltd. - Sanofi - Synthetic Biologics, Inc. - Teva Pharmaceutical Industries Limited - XenoPort, Inc. - Zydus Cadila Healthcare Limited Drug Profiles - (rifabutin clarithromycin clofazimine) - aldesleukin - ATL-1102 - ATXMS-1467 - AZ-17 - Cell Therapy for Relapsing Remitting Multiple Sclerosis - COG-133 - daclizumab - diazoxide - dimethyl fumarate - estriol - Gene Therapy for Relapsing and Remitting Multiple Sclerosis - glatiramer acetate ER - GSK-239512 - Guanabenz - HR-411 - hydralazine - imilecleucel-t - immune globulin (human) - interferon beta-1b - laquinimod sodium - MEDI-551 - MT-1303 - ofatumumab - olesoxime - opicinumab - Pegylated Interferon-Beta-1b - ponesimod - siponimod - Small Molecule to Target CTLA4 and IFNGR for RRMS - vatelizumab - VAY-736 - XP-23829 For more information visit http://www.researchandmarkets.com/research/hdmmpc/relapsing
MAPI: (), RDHL: 18.46 (+0.11), GSK: 42.45 (+0.65), XNPT: 6.79 (+0.16), SYN: 3.04 (+0.19), OPXA: 0.44 (-0.01), FWP: 39.47 (+1.55), TEVA: 61.38 (-0.75), ABBV: 69.23 (+1.26), NVS: 103.22 (+3.20)

Actelion Pharmaceuticals - R&D Investment And Returns
Saurabh Mishra - at Seeking Alpha - Thu Jul 02, 11:34AM CDT

Actelion creates Vaxxilon together with the Max Planck Society
Thomson Reuters ONE - Fri Jun 26, 12:00AM CDT
Actelion Pharmaceuticals Ltd / Actelion creates Vaxxilon together with the Max Planck Society . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

New data supporting gradual up-titration of ponesimod to mitigate first-dose cardiodynamic effects to be presented at EACPT 2015
Thomson Reuters ONE - Thu Jun 25, 12:00AM CDT
Actelion Pharmaceuticals Ltd / New data supporting gradual up-titration of ponesimod to mitigate first-dose cardiodynamic effects to be presented at EACPT 2015 . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

Gilead Patent for Sovaldi Rejected in China, Shares Down - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 22, 2:15PM CDT
Gilead Sciences Inc. was down approximately 1.2% after news sources revealed that company's patent application for Sovaldi has been rejected in China.
VRX: 232.32 (+8.93), GILD: 113.74 (+0.38), MYL: 71.22 (+0.87)

Epizyme Lead Candidate Effective in Ongoing Cancer Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 22, 10:50AM CDT
Epizyme, Inc. (EPZM) announced encouraging data from an ongoing phase I study on tazemetostat for B-cell non-Hodgkin lymphoma or advanced solid tumor.
GILD: 113.74 (+0.38), EPZM: 23.42 (+0.45), ACOR: 34.07 (+0.65)

Amgen Presents Interim Data on Migraine Drug AMG 334 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jun 22, 10:30AM CDT
Amgen (AMGN) presented encouraging 52-week interim open-label extension phase II study data on its migraine candidate, AMG 334.
AMGN: 154.10 (+2.79), TEVA: 61.38 (-0.75), LLY: 88.29 (+0.81)

Exelixis, Inc. (EXEL) in Focus: Stock Adds 7.5% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 22, 8:32AM CDT
Exelixis, Inc. (EXEL) was a big mover last session, as the company saw its shares rise nearly 8% on the day.
EXEL: 3.68 (+0.25)

Blueprint Medicines (BPMC) Falls: Stock Goes Down 7.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 22, 7:38AM CDT
Blueprint Medicines (BPMC) fell nearly 8% in the last trading session amid huge volumes, reversing its recent trend, as the stock is now up over 14% in the past one month.
BPMC: 28.02 (+2.16)

BioMarin Pharmaceutical Surges on Price Target Increase - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 19, 3:10PM CDT
BioMarin Pharmaceutical Inc. soared 12.2% after equity research analysts at several firms upped their price target for the stock.
VRX: 232.32 (+8.93), BMRN: 141.67 (+1.54), GILD: 113.74 (+0.38)

Amgen Cancer Drug Vectibix Hits Phase III Primary Endpoint - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 19, 3:05PM CDT
Amgen's (AMGN) Vectibix is found to improve overall survival in metastatic colorectal cancer patients who have not responded to chemotherapy.
AMGN: 154.10 (+2.79), LLY: 88.29 (+0.81), BMY: 69.27 (+1.38)

Momenta Gains on Generic Copaxone's Launch in U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 19, 2:20PM CDT
Momenta Pharmaceuticals' (MNTA) partner Sandoz initiated the launch of once-daily Glatopa (20mg) in the U.S.
TEVA: 61.38 (-0.75), MNTA: 21.76 (+0.49), NVS: 103.22 (+3.20)

Qiagen, Hitachi High-Technologies Ink Molecular Testing Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Jun 19, 1:10PM CDT
We believe this tie-up will elevate Qiagen's(QGEN) position in the rapidly changing and highly competitive markets of in-vitro diagnostics and life sciences, applying genetic engineering.
CBPO: 111.03 (+7.77), GILD: 113.74 (+0.38), QGEN: 25.73 (+1.00)

Momenta Pharmaceuticals (MNTA) in Focus: Stock Rises 6.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Jun 19, 8:18AM CDT
Momenta Pharmaceuticals Inc. (MNTA) was a big mover last session, as the company saw its shares rise around 7% on the day.
MNTA: 21.76 (+0.49)

KYTHERA Soars on $2.1 Billion Buyout Offer from Allergan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 18, 3:45PM CDT
Allergan (AGN) strikes a deal worth $2.1 billion to acquire KYTHERA Biopharmaceuticals and strengthen its facial aesthetics portfolio.
AGN: 312.13 (+8.03), GILD: 113.74 (+0.38), KYTH: 74.70 (-0.05)

Eli Lilly Reports Data on Migraine Drug; Inks Oncology Deals - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 18, 3:30PM CDT
Eli Lilly (LLY) announced positive data on migraine candidate, LY2951742; inks a couple of oncology deals.
GILD: 113.74 (+0.38), AZN: 66.45 (+1.90), LLY: 88.29 (+0.81)

Synergy Pharmaceuticals Soars on Constipation Drug Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 18, 3:25PM CDT
Synergy Pharmaceuticals Inc. (SGYP) announced encouraging top-line results from the first of two pivotal phase III studies on its lead pipeline candidate, plecanatide, in adults suffering from chronic idiopathic constipation.
SGYP: 9.13 (+0.49), VRX: 232.32 (+8.93), GILD: 113.74 (+0.38)

Qiagen's New Genetic Fingerprint Kits to Aid DNA Analysis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 18, 1:45PM CDT
To expand its footprint further in the forensic DNA analysis market, Qiagen (QGEN) is currently engaged in launching two new STR kits in the U.S.
CBPO: 111.03 (+7.77), GILD: 113.74 (+0.38), QGEN: 25.73 (+1.00)

Radius Health Up on Positive Data on Fracture Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Jun 18, 10:50AM CDT
Radius Health, Inc. (RDUS) announced positive combined data from the ACTIVExtend ACTIVE studies on abaloparatide-SC.
RDUS: 72.61 (+2.58), LLY: 88.29 (+0.81), BIOD: 1.02 (+0.04)

Teva Announces Positive Results on Tardive Dyskinesia Drug - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Jun 17, 4:00PM CDT
Teva Pharmaceutical Industries Ltd., (TEVA) announced positive top-line results from the ARM-TD study (Aim to Reduce Movements in Tardive Dyskinesia) on pipeline candidate SD-809.
VRX: 232.32 (+8.93), GILD: 113.74 (+0.38), TEVA: 61.38 (-0.75)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Dr. Anderson’s Journey: Leadership with Faith and Service

A Life Shaped by Service Dr. Howard Anderson isn't just another name in a glossy award roster—he's a powerhouse of leadership, a chaplain of compassion, and a soldier in spirit. Honored as a Pinnacle Professional Member of The Inner Circle of Excellence, his recognition feels less like an accolade and more like a testament to a life committed to serving others. The...

Franco-Nevada's Q3 Results Loom: Investors Ready

Gearing Up: Franco-Nevada's Q3 Numbers on the Horizon You know the drill! Franco-Nevada's third quarter results won't just trickle in—they'll set the tone for the months ahead. Mark your calendar: November 11th after the market closes is the magic hour when you'll get the skinny on their Q3 performance. The next morning, bright and early at 8:00 AM ET, they'll hash it...

Vayo Debuts as Booking Holdings Eyes $100M Investment

A travel revolution might just be on the horizon, courtesy of Booking Holdings' latest venture, Vayo. And they’re talking about throwing $100 million into it—subject to a few conditions, sure—but that’s not pocket change you toss around without a serious plan. Transforming Travel into a Seamless Experience Vayo’s got one job: making your travels less like a...

Laars Welcomes Women in Manufacturing to Facility Tour

Opening Doors and Minds in Manufacturing On October 15, Laars Heating Systems throws wide open its Rochester, N.H., facility to a group that's rewriting the rulebook: women in manufacturing. It's not just another day in the life of assembly lines and engineering desks, folks. This is about giving a platform to those often sidelined in the field of boilers and water...

AI-Powered Travel Transformation in Norway Revealed

AI-Driven Travel Meets Norway's Authentic Charm Well, folks, once again we're staring down the barrel of technology going full throttle in the travel game. Mindtrip, the savvy AI-powered travel platform, just inked a deal with the Norwegian Travel Cluster. It's their first tango in Europe, and they're not dipping their toes—they're diving headfirst into the icy fjords....

Wagner Logistics Gears Up for Major Expansion in Liberty

Imagine waking up to news like this: Wagner Logistics is laying down some serious roots in Liberty, MO. They’ve snagged a deal with a local manufacturer that’s got them renting out over 830,000 square feet of warehouse space. Seems Wagner's got a knack for living large. More Than Just a Warehouse Gig Wagner's not just popping up another dusty shelf space; they're...

Paradigm Therapeutics: A Beacon in Rare Diseases

A Step Towards Recognition You know the old saying: innovation never sleeps. Well, Paradigm Therapeutics seems to have taken that to heart. The company's embarked on a peculiar yet promising journey with SD-101 (Zorblesia™), and here they are, basking in the glow of another nomination for the 2026 Prix Galien USA "Best Start-Up" award. It’s their second shot at this...

Puori Protein Transparency Pays Off Amid Lead Scare

Puori's Moment of Reckoning The world of nutritional supplements is no stranger to controversy, but when Puori found itself caught in the storm of the Consumer Reports investigation last year, it chose a road less traveled: transparency and accountability. Faced with alarming news that over two-thirds of tested protein powders exceeded California's Proposition 65 lead...

Home Buying: Unmasking All the Real Budget Costs

Home Buying: More Costs Than Meets the Eye Let's face it, buying a home is no stroll in the park. It's a tangled web of numbers and surprises that can leave even the savviest buyer in a daze. Thank goodness for articles like the one from HelloNation featuring Serena LoPiccolo-Smith, which make the invisible visible when it comes to the financial intricacies of home...

Marshall Goldman Expands Footprint with Marino Acquisition

Revving Up in Florida: Marshall Goldman's Strategic Leap If you're tuned into the luxury car scene, you probably already heard Marshall Goldman is making moves into Florida. Buying Marino Performance Motors of West Palm Beach isn't just another notch on their belt—it's a strategic leap into their second-largest market. This ain't merely about showroom floor space. Think...